Carlton Schwab, MD
Gynecologic Oncology · Spartanburg, SCNPI 1700014982
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $977 of the $1,094 with a category attached, or 89.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $391, 2.0 times the $194 reported in 2019.
Across 49 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$173
- AbbVie$153
- Merck$149
- GSK$123
- Clovis Oncology, Inc.$92
- AstraZeneca$85
- plus $318 from 13 others
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$2K
What the payments were for
- Food & beverage$97789%
- Education$11611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 7 | $173 |
| AbbVie | 5 | $153 |
| Merck | 7 | $149 |
| GSK | 6 | $123 |
| Clovis Oncology, Inc. | 3 | $92 |
| AstraZeneca | 4 | $85 |
| Genmab U.S., Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Baxter Healthcare | 1 | $32 |
| Pfizer | 2 | $32 |
| Astellas Pharma US Inc | 1 | $25 |
| Kyowa Kirin, Inc. | 2 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $19 |
| Aspira Women's Health Inc | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Tesaro, Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $14 |
| Intuitive Surgical | 1 | $5 |
How this compares
Too few gynecologic oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 72 | $3,866 |
| Exemestane | 22 | $1,243 |
| Megestrol Acetate | 21 | $880 |
| Gabapentin | 123 | $713 |
| Ondansetron Hcl | 118 | $654 |
| Clobetasol Propionate | 17 | $504 |
| Olanzapine | 22 | $483 |
| Prochlorperazine Maleate | 44 | $362 |
| Chlorhexidine Gluconate | 76 | $235 |
| Tamoxifen Citrate | 20 | $230 |
| Mirtazapine | 17 | $218 |
| Ibuprofen | 56 | $208 |
| Medroxyprogesterone Acetate | 13 | $188 |
| Nystatin | 18 | $183 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $178 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Spartanburg
- James HunterSpartanburg$89
- Whitney GraybillCharleston$81K
- William MerrittColumbia$9K
- Mark MillerWest Columbia$8K
- James WilliamsColumbia$8K
- Courtney BaileyCharleston$5K
- Jonathan FooteCharleston$3K
- Catherine WatsonCharleston$3K
- Brian OrrCharleston$3K
- Larry PulsGreenville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.